Effects of Whole Body Vibration in Different Devices on Bone and Muscle Mass in Postmenopausal Women
Launched by UNIVERSIDADE ESTADUAL DO NORTE DO PARANA · Jan 15, 2024
Trial Information
Current as of July 22, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of whole-body vibration (WBV) on bone and muscle health in postmenopausal women. As women go through menopause, they often experience a decrease in bone density and muscle mass, which can lead to a higher risk of falls and a lower quality of life. The trial aims to see how different types of vibration therapy—using either triplanar (synchronous) or side-alternating devices—affect these health factors over a period of 12 months. Participants will be assessed on their bone density, muscle mass, physical performance, and overall quality of life at the beginning, six months in, and at the end of the study.
To be eligible for this trial, women must be postmenopausal, meaning they haven't menstruated for at least a year, and they should not have been regularly exercising for the past six months. Additionally, they should be able to perform daily tasks independently and have no serious medical conditions that would interfere with the study. Over the course of the trial, participants will attend sessions three times a week, where they'll engage in WBV exercises and undergo various assessments to track their progress. This study hopes to provide valuable insights into improving health and quality of life for postmenopausal women.
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Being postmenopausal (without menstruating for at least 12 months);
- • Not performing physical exercise systematically for at least 6 months;
- • Not needing assistance to carry out daily tasks;
- • Do not present serious cognitive problems that make it impossible to understand simple commands;
- • Do not have serious dysfunctions or implants in the spine, hips or lower limbs;
- • Not have neurological diseases or diseases that affect bone metabolism;
- • Do not have vascular diseases, arrhythmia, use a pacemaker, suffer from epilepsy or seizures;
- • No diseases/problems that affect the retina;
- • Do not present severe labyrinthitis or vertigo;
- • Not using medication/supplements to increase bone and/or muscle mass for at least 6 months;
- • Have not undergone cancer treatment in the last 5 years.
- Exclusion Criteria:
- • Withdraw from participating in the study for any reason;
- • Present adverse events during interventions that cannot be controlled.
About Universidade Estadual Do Norte Do Parana
Universidade Estadual do Norte do Paraná (UENP) is a prominent educational institution dedicated to advancing research and healthcare through innovative clinical trials. With a focus on improving patient outcomes and contributing to the scientific community, UENP collaborates with various stakeholders to conduct rigorous studies that adhere to ethical standards and best practices. The university's commitment to excellence in research is reflected in its multidisciplinary approach, which fosters collaboration among healthcare professionals, researchers, and students, ultimately enhancing the quality of clinical research and its impact on public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Jacarezinho, Paraná, Brazil
Jacarezinho, , Brazil
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported